logo
Plus   Neg
Share
Email

Endo: Novitium Pharma Gets FDA Approval For Generic Equivalent Of Orfadin

Endo International plc (ENDP) said Novitium Pharma, a partner of Endo's subsidiary, has received approval from the FDA for a generic equivalent of Swedish Orphan Biovitrum's Orfadin. The Nitisinone capsules are used to treat patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Endo's operating company, Par Pharmaceutical Inc., plans to sell the product through specialty pharmacies beginning September.

Shares of Endo International plc were up more than 4 percent in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
House-Autry Mills, Inc. issued a recall for its 9 ounce bottles of House-Autry Tartar Sauce due to the co-manufacturer's verification of spoilage associated with the product, according to a statement published by the U.S. Food and Drug Administration or FDA. The North Carolina-based company said the product may be unsuitable for consumption. Kimberly-Clark Corp. (KMB) on Monday reported a profit for the fourth quarter that edged down from last year, hurt by higher expenses, despite 6 percent sales growth. Both adjusted earnings per share and net sales topped analysts' expectations. The company also initiated adjusted earnings and net sales growth guidance for the full-year 2021. Shares of Philips Electronics NV were gaining around 3 percent in Amsterdam trading after the Dutch consumer electronics giant reported Monday higher results in its fourth quarter. The company also proposed dividend, and said it sees growth in fiscal 2021 comparable sales and adjusted margin.
Follow RTT